Artemisinin Combination Therapy Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2027

The report on the global artemisinin combination therapy market provides qualitative and quantitative analysis for the period from 2019 to 2027. The report predicts the global artemisinin combination therapy market to grow with a CAGR of 8% over the forecast period from 2021-2027. The study on artemisinin combination therapy market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2019 to 2027.

The report on artemisinin combination therapy market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global artemisinin combination therapy market over the period of 2019 to 2027. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global artemisinin combination therapy market over the period of 2019 to 2027. Further, IGR- Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings

1) Drivers

• Prevalence of malaria in under-developing countries
• Growing accessibility of artemisinin combination therapy market

2) Restraints

• High cost of artemisinin combination therapy courses

3) Opportunities

• Growing R&D of new artemisinin combination therapies

Research Methodology

A) Primary Research

The primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents who are approached include

1. Key Opinion Leaders associated with the Publisher
2. Internal and External subject matter experts
3. Professionals and participants from the industry

The primary research respondents typically include:

1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/ country managers
5. Vice President level executives.

B) Secondary Research

Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. At the publisher, each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include:

1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies

Segments Covered

The global artemisinin combination therapy market is segmented on the basis of therapy type, and distribution channel.

The Global Artemisinin Combination Therapy Market by Therapy Type

• Artesunate-amodiaquine
• Artemether-lumefantrine
• Dihydroartemisinin-piperaquine
• Artesunate-sulfadoxine-pyrimethamine
• Pyronaridine-artesunate
• Artesunate-mefloquine

The Global Artemisinin Combination Therapy Market by Distribution Channel

• Hospitals
• Clinics and Pharmacies
• Retail and Drug Stores
• Others

Company Profiles

The companies covered in the report include:

• Novartis AG
• Cipla Ltd
• Sanofi SA
• Desano Holdings Ltd.,
• KPC Pharmaceuticals Inc.
• Guilin Pharmaceuticals
• Calyx Chemicals and Pharmaceuticals Ltd.
• DENK PHARMA GmbH & Co. KG
• Mylan N.V.
• Hovid Berhad

What does this Report Deliver?

1. Comprehensive analysis of the global as well as regional markets of the artemisinin combination therapy market.
2. Complete coverage of all the segments in the artemisinin combination therapy market to analyze the trends, developments in the global market and forecast of market size up to 2027.
3. Comprehensive analysis of the companies operating in the global artemisinin combination therapy market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. IGR- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

This product will be delivered within 1-3 business days.